Log in to your Inderes Free account to see all free content on this page.

OncoZenge

5.4

SEK

-9.09 %

Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

-9.09%

-13.46%

+44%

+44%

-15.49%

+58.82%

-36.32%

-

-55.87%

OncoZenge is a Swedish pharmaceutical company that develops treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. After completing phase 2 studies, the company's product candidate is under further development as a basis for applying for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Market cap

63.25M SEK

Turnover

578.21K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

15.5.

2025

Interim report Q1'25

28.5.

2025

General meeting '25

21.8.

2025

Interim report Q2'25

All

Press releases

ShowingAll content types

Regulatory press release3/28/2025, 7:00 AM

OncoZenge AB enters exclusive agreement with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

Press release3/4/2025, 3:00 PM

OncoZenge AB receives positive assessment regarding the PCT-patent application for BupiZenge™

Regulatory press release1/27/2025, 6:00 PM

OncoZenge AB: OncoZenge enters into SEK 30.2 million investment agreement with new strategic investor Sichuan Yangtian Bio-Pharmaceutical, intended to be carried out through directed share issues

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Press release1/16/2025, 2:02 PM

OncoZenge AB files PCT patent application for BupiZenge™

Regulatory press release1/13/2025, 4:30 PM

OncoZenge AB has entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

Press release11/26/2024, 10:30 AM

Redeye: OncoZenge - Down, but not out

Press release11/18/2024, 9:27 AM

Redeye: OncoZenge Q3 2024 - Approaching lift-off

Press release10/31/2024, 8:25 AM

Redeye: Redeye Initiates Coverage of OncoZenge

Regulatory press release10/18/2024, 8:00 AM

OncoZenge AB intends to enter partnership with Pharmanovia for commercialization of BupiZenge™ in Europe, Middle East & North Africa

Press release6/4/2024, 3:15 PM

OncoZenge AB: OncoZenge participates in MASCC cancer care conference June 27-29

Press release4/26/2024, 12:00 PM

OncoZenge AB: OncoZenge Appoints Anna Asplind as Phase 3 Program Manager

Press release4/25/2024, 12:40 PM

OncoZenge AB: OncoZenge Releases Paper on BupiZenge™ Addressing Unmet Medical Needs

Press release4/9/2024, 11:00 AM

OncoZenge AB: OncoZenge Appoints Åsa Nilsson as Clinical Research Manager

Press release4/8/2024, 7:30 AM

OncoZenge AB: OncoZenge Announces Dr. Paolo Bossi as New Member of the Advisory Board

Press release4/4/2024, 1:01 PM

OncoZenge AB: OncoZenge Announces Read-out of Positive Stability Data for BupiZenge™

Press release3/11/2024, 12:00 PM

OncoZenge AB: OncoZenge Explores Strategic Options for BupiZenge™ in China

Press release2/7/2024, 10:00 AM

OncoZenge AB: OncoZenge Files Patent Application for Strengthened IP Protection for BupiZenge™

Press release1/2/2024, 2:52 PM

OncoZenge AB: OncoZenge submits application for PRIME status in the EU

Press release12/13/2023, 4:21 PM

OncoZenge AB: OncoZenge Announces Advisory Board with Dr Stephen Sonis and Dr Pooja Nandwani Patel

Regulatory press release11/28/2023, 1:15 PM

OncoZenge AB: Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge™ in the United States

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.